SiNtx Technologies Inc (SINT)

[boston745]

In a previous post i said that if Sintx was properly valued there would not be as many offerings, shares issued per offering, or reverse splits. To show just how much first, look at the previous post which breaks down the various industries and products Sintx materials can be used for. Then research a comparable company Implex, acquired in 2003, to see how much Sintx Si3N4 is worth in the few markets that Implex Hydrocel (Zimmer's Trabecular Metal) is used in. Keep in mind that Si3n4 brings superior benefits with it compared to that of Trabecular Metal (biodegradable, antimicrobial, more osseointegrative, can be imbued and used as a coating in/on other materials), has a larger market reach as it can be used for industrial, energy, aerospace, defense, anti-pathogenic, other medical products, & even cancer treatment. Consider how much those markets are all worth. Implex couldnt touch all that but it does provide a baseline valuation for Sintx IP as it was a materials company as well.

Total acquisition costs of Implex was $108m upfront + $124.1 (96m+28.1) in cash earn-out payments from 2004-2006 for a grand total of $232.1m. Sintx tried to IPO for a valuation of around $225m in 2007 when it only had spinal product candidates and hip/knee candidates in early stages of R&D.

The pending acquisition of Implex gives the Company enhanced flexibility in the development of products using Trabecular Metal Technology, which the Company believes has significant potential in orthopaedic reconstructive and spinal product applications.

The markets referenced here in Zimmers 10k are just a couple of markets Sintx Si3n4 can be used in.

Each share of Implex stock will be converted into the right to receive cash having an aggregate value of approximately $108 million at closing and additional cash earn-out payments that are contingent on the growth of Implex product sales through 2006.

We have paid $96.0 million of earn-out payments through December 31, 2005. We estimate remaining payments, which will occur in 2006, to be in a range from $30 million to $40 million.

In 2006, we made a final payment of $28.1 million pursuant to the terms of the Implex acquisition agreement for contingent earn-out payments.

Quote Sources:
https://www.sec.gov/Archives/edgar/data/1136869/000095013704001881/c83286e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013706002478/c02799e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013707002904/c12593e10vk.htm

Yes, yes, yes. Yes, thanks to Gavin,
EndFrame, a middle-out
compression platform,
is objectively worth $250 million.

Laurie couldn't vote for the platform
because she couldn't assign
a dollar value to it.
Well, Gavin has just done that.
He's validated the market,

Thus using this same logic, as Sintx is a materials company for ortho industry as Implex was, Zimmer set Sintx value for its ortho products at $232m back in 2003; Sintx tried to IPO with a valution of $225m in 2007. With inflation in market size over the last 20 years its ortho potential is worth even more. Thats not even factoring in armor, aerospace, energy, anti-pathogenic, & other potential medtech products.

========================================

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017

This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research

2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear